Cargando…
Risk of discontinuation of Advanced Therapy Medicinal Products clinical trials
OBJECTIVE: Advanced therapy medicinal products (ATMPs) constitute a class of innovative products that encompasses gene therapy, somatic cell therapy, and tissue-engineered products (TEP). There is an increased investment of commercial and non-commercial sponsors in this field and a growing number of...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Co-Action Publishing
2016
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4973442/ https://www.ncbi.nlm.nih.gov/pubmed/27570614 http://dx.doi.org/10.3402/jmahp.v4.32232 |